FAQ on Clene Inc.'s Q2 2025 Results and ALS Therapy NDA Submission Plans

What is Clene Inc. focusing on with its Q2 2025 results announcement?

Clene Inc. is focusing on its financial stability, with sufficient cash runway into Q1 2026, and its progress towards submitting a New Drug Application for its ALS therapy, CNM-Au8, by the end of 2025.

What is CNM-Au8 and what does it target?

CNM-Au8 is an investigational first-in-class therapy developed by Clene Inc. that aims to improve central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway, while reducing oxidative stress, primarily for neurodegenerative diseases like ALS.

When does Clene Inc. plan to submit the New Drug Application for CNM-Au8?

Clene Inc. plans to submit the New Drug Application for CNM-Au8 under the FDA’s accelerated approval pathway for ALS by the end of 2025.

What steps is Clene Inc. taking to support its NDA submission for CNM-Au8?

Clene Inc. is meeting with the FDA to review survival data for CNM-Au8 in ALS and preparing analyses of NIH-sponsored Expanded Access Program neurofilament light biomarker data, expected in Q4 2025, to support the NDA submission.

Where can I find more information about Clene Inc. and its developments?

More information about Clene Inc. and its developments can be found on its website at www.clene.com, or by following the company on X (formerly Twitter) and LinkedIn.

What is the significance of Clene Inc.’s work on CNM-Au8 for the ALS community?

Clene Inc.’s work on CNM-Au8 represents a potential impactful therapy for the ALS community, aiming to address the urgent need for treatments that can improve survival and neuronal function in patients with this neurodegenerative disease.

How does Clene Inc. plan to fund its operations into 2026?

Clene Inc. reported that it has sufficient cash runway to fund its operations into Q1 2026, indicating financial stability as it progresses towards its NDA submission for CNM-Au8.

What are the next steps for Clene Inc. following its Q2 2025 results?

Following its Q2 2025 results, Clene Inc.’s next steps include meeting with the FDA to review survival data for CNM-Au8 and preparing biomarker data analyses to support its year-end NDA submission for ALS therapy.